ICU Medical, Inc. $ICUI Shares Purchased by Gabelli Funds LLC

Gabelli Funds LLC lifted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 8.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 76,500 shares of the medical instruments supplier’s stock after acquiring an additional 6,000 shares during the period. Gabelli Funds LLC’s holdings in ICU Medical were worth $10,109,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Moody National Bank Trust Division raised its position in shares of ICU Medical by 0.9% during the 2nd quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock valued at $1,421,000 after acquiring an additional 93 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of ICU Medical by 1.8% during the second quarter. Maryland State Retirement & Pension System now owns 7,233 shares of the medical instruments supplier’s stock worth $956,000 after purchasing an additional 129 shares during the period. Blue Trust Inc. lifted its position in shares of ICU Medical by 17.6% in the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 141 shares during the last quarter. Teacher Retirement System of Texas lifted its position in shares of ICU Medical by 4.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,548 shares of the medical instruments supplier’s stock worth $469,000 after buying an additional 148 shares during the last quarter. Finally, F m Investments LLC boosted its holdings in shares of ICU Medical by 0.6% in the 2nd quarter. F m Investments LLC now owns 25,958 shares of the medical instruments supplier’s stock valued at $3,430,000 after buying an additional 149 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the sale, the director owned 3,995 shares in the company, valued at $560,977.90. This represents a 24.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at $776,607.04. This represents a 14.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.50% of the company’s stock.

ICU Medical Stock Up 0.9%

ICU Medical stock opened at $143.77 on Tuesday. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $175.51. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -463.76 and a beta of 0.82. The company’s 50-day moving average price is $129.97 and its two-hundred day moving average price is $128.88. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. During the same period last year, the firm posted $1.59 earnings per share. The business’s revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Piper Sandler increased their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, KeyCorp boosted their price objective on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $181.75.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.